Sociedad Americana de Hirudoterapia

Dextran-related complications in head and neck microsurgery: do the benefits outweigh the risks? A prospective randomized analysis.

Randomized controlled trial published in Plastic and reconstructive surgery (2003)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Randomized controlled trialEnsayos clínicosDesarrollo de fármacosDisa et al. · Plastic and reconstructive surgery, 2003

Abstract

Increased experience with free-tissue transfer has minimized flap loss secondary to microvascular thrombosis, yet pharmacologic antithrombotic prophylaxis continues to be used routinely. Currently there is no consensus on the ideal pharmacologic agent, dosing, or efficacy. Low-molecular-weight dextran has been widely used for prophylaxis due to its properties of volume expansion and enhanced microrheology. Significant systemic morbidity (pulmonary morbidity, cardiac morbidity, anaphylaxis) is known to occur with use of low-molecular-weight dextran. The purpose of this study was to evaluate morbidity associated with postoperative low-molecular-weight dextran and aspirin prophylaxis in head and neck microsurgery patients. This study was a randomized prospective analysis of 100 consecutive patients undergoing microvascular reconstruction for head and neck malignancy during a 2-year period. Patients were randomized into one of three postoperative antithrombotic prophylaxis treatment groups: low-molecular-weight dextran 20 cc/hour for 48 hours (n = 35), low-molecular-weight dextran 20 cc/hour for 120 hours (n = 32), or aspirin 325 mg/day for 120 hours (n = 27). Six patients were excluded intraoperatively due to the need for systemic heparin therapy. Treatment groups were compared for age, sex, prior medical problems, duration of anesthesia, and intraoperative fluid intake. Flap outcome and the incidence of local and systemic complications were evaluated in the treatment groups. Patient ages ranged from 12 to 84 years (mean age, 58 years). No significant difference was found among the treatment groups with respect to age, sex, prior medical problems, duration of anesthesia, intraoperative fluid intake, and the distribution of donor and recipient sites. There were no total flap losses and two partial flap losses in this series. Three flaps were reexplored and all were salvaged. The incidence of systemic complications (congestive heart failure, myocardial infarction, pulmonary edema, pleural effusion, and pneumonia) was as follows: low-molecular-weight dextran 120 hours, 51 percent; low-molecular-weight dextran 48 hours, 29 percent; and aspirin, 7 percent. Analysis of these data suggests that the method of prophylaxis had no effect on overall flap survival. However, the incidence of systemic complications was significantly related to the method of prophylaxis, with patients receiving low-molecular-weight dextran 120 hours and 48 hours at a 7.2 and 3.9 times greater relative risk, respectively, of developing a systemic complication compared with patients receiving aspirin. The results of this study have eliminated the routine use of low-molecular-weight dextran prophylaxis at our institution in an effort to reduce morbidity in head and neck microsurgical reconstruction.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeClinical TrialJournal ArticleRandomized Controlled Trial
Indexed MeSH termsAdolescentAdultAgedAged, 80 and overAnticoagulantsAspirinChildDextransFemaleHead and Neck NeoplasmsHumansMale

Resumen

Increased experience with free-tissue transfer has minimized flap loss secondary to microvascular thrombosis, yet pharmacologic antithrombotic prophylaxis continues to be used routinely. Currently there is no consensus on the ideal pharmacologic agent, dosing, or efficacy.

Por qué esto importa para la hirudoterapia

Este ensayo prospectivo aleatorizado comparó la morbilidad asociada al dextrano de bajo peso molecular frente a la aspirina para la profilaxis antitrombótica postoperatoria en 100 pacientes de microcirugía de cabeza y cuello distribuidos en tres grupos de tratamiento. El estudio no registró pérdidas totales del colgajo ni encontró diferencias significativas en la supervivencia del colgajo entre los grupos, pero las tasas de complicaciones sistémicas fueron del 51 % con dextrano durante 120 horas, del 29 % con dextrano durante 48 horas y del 7 % con aspirina, lo que se traduce en un riesgo relativo 3,9–7,2 veces mayor con dextrano frente a aspirina. Estos resultados llevaron a la institución a suspender la profilaxis rutinaria con dextrano. ADVERTENCIA: Este estudio no involucra de ningún modo a sanguijuelas, hirudina, hirudoterapia o compuestos derivados de sanguijuelas, y no existe un vínculo defendible con las sanguijuelas en el ámbito de la ASH.

Citación

Dextran-related complications in head and neck microsurgery: do the benefits outweigh the risks? A prospective randomized analysis.

Disa et al. · Plastic and reconstructive surgery, 2003

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.